Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD

0.857  +0.01 (+0.85%)

After market: 0.92 +0.06 (+7.35%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PRLD. PRLD was compared to 551 industry peers in the Biotechnology industry. The financial health of PRLD is average, but there are quite some concerns on its profitability. PRLD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year PRLD has reported negative net income.
PRLD had a negative operating cash flow in the past year.
In the past 5 years PRLD always reported negative net income.
In the past 5 years PRLD always reported negative operating cash flow.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of PRLD (-72.46%) is worse than 65.15% of its industry peers.
Looking at the Return On Equity, with a value of -96.74%, PRLD is in line with its industry, outperforming 46.10% of the companies in the same industry.
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROIC N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PRLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

5

2. Health

2.1 Basic Checks

PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRLD has more shares outstanding
The number of shares outstanding for PRLD has been increased compared to 5 years ago.
Compared to 1 year ago, PRLD has a worse debt to assets ratio.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PRLD has an Altman-Z score of -5.83. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.83, PRLD is doing worse than 62.98% of the companies in the same industry.
PRLD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.83
ROIC/WACCN/A
WACC10.85%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 5.30 indicates that PRLD has no problem at all paying its short term obligations.
PRLD has a Current ratio (5.30) which is in line with its industry peers.
A Quick Ratio of 5.30 indicates that PRLD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.30, PRLD is in line with its industry, outperforming 57.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.3
Quick Ratio 5.3
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

3

3. Growth

3.1 Past

PRLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.63%, which is quite good.
EPS 1Y (TTM)9.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 9.21% on average over the next years. This is quite good.
PRLD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.13% yearly.
EPS Next Y6.09%
EPS Next 2Y14%
EPS Next 3Y13.31%
EPS Next 5Y9.21%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y94.13%

3.3 Evolution

PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2028 2029 2030 2031 2032 100M 200M 300M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRLD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRLD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PRLD's earnings are expected to grow with 13.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14%
EPS Next 3Y13.31%

0

5. Dividend

5.1 Amount

PRLD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (8/7/2025, 8:00:01 PM)

After market: 0.92 +0.06 (+7.35%)

0.857

+0.01 (+0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners44.67%
Inst Owner Change0.27%
Ins Owners11.37%
Ins Owner Change25.52%
Market Cap48.39M
Analysts80
Price Target3.83 (346.91%)
Short Float %1.88%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.12%
Min EPS beat(2)10.65%
Max EPS beat(2)19.59%
EPS beat(4)3
Avg EPS beat(4)10.12%
Min EPS beat(4)-4.88%
Max EPS beat(4)19.59%
EPS beat(8)7
Avg EPS beat(8)13.26%
EPS beat(12)11
Avg EPS beat(12)10.59%
EPS beat(16)11
Avg EPS beat(16)6.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.36%
EPS NY rev (1m)0%
EPS NY rev (3m)4.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.91
P/FCF N/A
P/OCF N/A
P/B 0.37
P/tB 0.37
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0.12
BVpS2.33
TBVpS2.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.12%
Cap/Sales 10.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.3
Quick Ratio 5.3
Altman-Z -5.83
F-Score4
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)190.81%
Cap/Depr(5y)187.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y6.09%
EPS Next 2Y14%
EPS Next 3Y13.31%
EPS Next 5Y9.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y94.13%
EBIT growth 1Y-5.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.9%
OCF growth 3YN/A
OCF growth 5YN/A